These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476 [TBL] [Abstract][Full Text] [Related]
4. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699 [TBL] [Abstract][Full Text] [Related]
5. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Lamm D; Brausi M; O'Donnell MA; Witjes JA Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309 [TBL] [Abstract][Full Text] [Related]
6. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. Abufaraj M; Mostafid H; Shariat SF; Babjuk M Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122 [TBL] [Abstract][Full Text] [Related]
7. Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis. Wu C; Zhou X; Miao C; Zhang J; Tang Q; Chang X; Ni H Cell Physiol Biochem; 2017; 41(4):1298-1312. PubMed ID: 28278504 [TBL] [Abstract][Full Text] [Related]
11. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466 [TBL] [Abstract][Full Text] [Related]
12. Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. Yates DR; Rouprêt M BJU Int; 2010 Jul; 106(2):162-7. PubMed ID: 20201829 [TBL] [Abstract][Full Text] [Related]
13. Management of high-risk non-muscle invasive bladder cancer. Brausi M; Olaru V Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212 [TBL] [Abstract][Full Text] [Related]
14. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E; Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624 [TBL] [Abstract][Full Text] [Related]
15. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). Álvarez-Maestro M; Guerrero-Ramos F; Rodríguez-Faba O; Domínguez-Escrig JL; Fernández-Gómez JM Actas Urol Esp (Engl Ed); 2021 Mar; 45(2):93-102. PubMed ID: 33012593 [TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra. Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432 [TBL] [Abstract][Full Text] [Related]
18. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options. Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552 [TBL] [Abstract][Full Text] [Related]
19. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA; Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758 [TBL] [Abstract][Full Text] [Related]
20. Intravesical therapy for bladder cancer. Williams SK; Hoenig DM; Ghavamian R; Soloway M Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]